FDA gives nod to Medtronic's diabetes decision support software
The FDA has approved Medtronic’s CareLink Pro 3.0 Therapy Management Software, a software program that offers decision support to healthcare professionals managing diabetes. The company announced a market launch in the U.S.
The software analyzes data from a patient’s insulin pump, continuous glucose monitoring device and blood glucose meter to identify patient information in one dashboard. In addition, the Minneapolis-based Medtronic said it pinpoints the times the patient experienced a hypoglycemic or hyperglycemic glucose pattern and prioritizes these patterns so that clinicians know which times of day are the biggest challenges for their patients.
The software analyzes data from a patient’s insulin pump, continuous glucose monitoring device and blood glucose meter to identify patient information in one dashboard. In addition, the Minneapolis-based Medtronic said it pinpoints the times the patient experienced a hypoglycemic or hyperglycemic glucose pattern and prioritizes these patterns so that clinicians know which times of day are the biggest challenges for their patients.